UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 40

Sortiert nach

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Clinical and translational science, 2022-04, Vol.15 (4), p.954-966

2022

Link zum Volltext

Verfügbarkeit prüfen

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Journal for immunotherapy of cancer, 2024-03, Vol.12 (3), p.e008338

2024

Link zum Volltext

Verfügbarkeit prüfen

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

British journal of haematology, 2022-11, Vol.199 (3), p.366-370

2022

Link zum Volltext

Verfügbarkeit prüfen

Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model

Theranostics, 2016-01, Vol.6 (8), p.1119-1130

2016

Link zum Volltext

Verfügbarkeit prüfen

A single-center experience with undifferentiated embryonal sarcoma of the liver

Pediatric blood & cancer, 2016-12, Vol.63 (12), p.2246-2248

2016

Link zum Volltext

Verfügbarkeit prüfen

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

Molecular oncology, 2014-03, Vol.8 (2), p.323-336

2014

Link zum Volltext

Verfügbarkeit prüfen

BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

Oncotarget, 2016-07, Vol.7 (28), p.43062-43075

2016

Link zum Volltext

Verfügbarkeit prüfen

Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma

Journal of pediatric hematology/oncology, 2017-11, Vol.39 (8), p.e443-e445

2017

Link zum Volltext

Verfügbarkeit prüfen

Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2 in patients with thalassemia major on various chelation regimens: A 6‐year study

American journal of hematology, 2013-08, Vol.88 (8), p.652-656

2013

Link zum Volltext

Verfügbarkeit prüfen

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Cell, 2020-08, Vol.182 (4), p.1044-1061.e18

2020

Link zum Volltext

Verfügbarkeit prüfen

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Blood, 2022-11, Vol.140 (Supplement 1), p.8855-8856

2022

Link zum Volltext

Verfügbarkeit prüfen

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.11579-11580

2022

Link zum Volltext

Verfügbarkeit prüfen

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

Blood, 2022-11, Vol.140 (Supplement 1), p.11912-11913

2022

Link zum Volltext

Verfügbarkeit prüfen

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Blood, 2022-11, Vol.140 (Supplement 1), p.11930-11931

2022

Link zum Volltext

Verfügbarkeit prüfen

Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T)

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.e19351-e19351

2020

Link zum Volltext

Verfügbarkeit prüfen

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Blood, 2022-11, Vol.140 (Supplement 1), p.11560-11561

2022

Link zum Volltext

Verfügbarkeit prüfen

Superior vena cava syndrome in children

Indian journal of hematology & blood transfusion, 2008-03, Vol.24 (1), p.28-30

2008

Link zum Volltext

Verfügbarkeit prüfen

The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.10533-10533

2018

Link zum Volltext

Verfügbarkeit prüfen

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Blood, 2022-11, Vol.140 (Supplement 1), p.1070-1071

2022

Link zum Volltext

Verfügbarkeit prüfen

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Blood, 2022-11, Vol.140 (Supplement 1), p.5198-5200

2022

Link zum Volltext

Verfügbarkeit prüfen

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Blood, 2019-11, Vol.134 (Supplement_1), p.4007-4007

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 40

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(39)
Buchkapitel
(1)

Sprache

Englisch
(40)

Erscheinungsjahr

n.n

Thema

Humans
(11)
Life Sciences & Biomedicine
(8)
Science & Technology
(8)
Hematology
(5)
Male
(5)
Oncology
(5)
Animals
(4)
Female
(4)
Patients
(4)
Adolescent
(3)
Antibodies, Bispecific
(3)
Antigens, Cd20
(3)
Antineoplastic Agents - Therapeutic Use
(3)
Ewing Sarcoma
(3)
Lymphoma
(3)
Mice
(3)
Antibodies
(2)
Biomarkers
(2)
Biopsy
(2)
Bispecific Antibodies
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Translational findings for odronextamab: From preclinical research to a first‐in‐human study in patients with CD20+ B‐cell malignancies

Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy

Recapitulating the Size and Cargo of Tumor Exosomes in a Tissue-Engineered Model

A single-center experience with undifferentiated embryonal sarcoma of the liver

Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

BO-1055, a novel DNA cross-linking agent with remarkable low myelotoxicity shows potent activity in sarcoma models

Intracardiac Low-grade Sarcoma Following Treatment for Ewing Sarcoma

Longitudinal monitoring of cardiac siderosis using cardiovascular magnetic resonance T2 in patients with thalassemia major on various chelation regimens: A 6‐year study

Extracellular Vesicle and Particle Biomarkers Define Multiple Human Cancers

Selection of Odronextamab Pediatric Dosing Regimens for Aggressive Non-Hodgkin Lymphoma Via a Modeling and Simulation Approach

Modeling and Simulation in Support of Odronextamab Subcutaneous Dose Selection for Adult Patients with Indolent or Aggressive Non-Hodgkin Lymphoma

Evaluate Dynamics of IL-6 Release during Step-up Dosing of Subcutaneous Administration of Odronextamab Via a Quantitative Systems Pharmacology Modeling Approach

A Quantitative Systems Pharmacology Modeling Framework for Evaluation of Cytokine Release Mediated By Intravenous Odronextamab Monotherapy in Patients with B-Cell Non-Hodgkin Lymphoma

Real-world treatment patterns among patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19-directed chimeric antigen receptor T-cell therapy (CAR T)

Optimization of Intravenous Odronextamab Step-up Regimen for Reducing the Risk of High-Grade Cytokine Release Syndrome

Superior vena cava syndrome in children

The addition of cycles of irinotecan/temozolomide (i/T) to cycles of vincristine, doxorubicin, cyclophosphamide (VDC) and cycles of ifosfamide, etoposide (IE) for the treatment of Ewing sarcoma (ES)

Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)

Odronextamab in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Grade 1-3a: Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2

A Phase 2 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody (Ab), in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)

Odronextamab (REGN1979), a Human CD20 x CD3 Bispecific Antibody, Induces Durable, Complete Responses in Patients with Highly Refractory B-Cell Non-Hodgkin Lymphoma, Including Patients Refractory to CAR T Therapy

A Phase 2 Study of Odronextamab (REGN1979), a CD20 x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Suchergebnisse filtern